

**SUBJECTIVE:** Ms. Meyer connects via video visit today for routine check-in. She is ~6 months into treatment with Osimertinib for Stage IV EGFR L858R positive lung adenocarcinoma. Reports feeling "very well." Has excellent energy, no cough, no shortness of breath, no bone pain (initial site of mets). Tolerating Osimertinib 80mg daily without difficulty. Notes only very mild dry skin on hands, managed easily with moisturizer. Denies rash, diarrhea, stomatitis, nail changes, or other common side effects. Adherence >95%.

**PERTINENT HISTORY:** Diagnosed Jan 25, 2023 after presenting with persistent R rib pain. Staging PET/CT showed LUL primary nodule (1.5cm) and FDG-avid metastases in multiple ribs and T-spine. Brain MRI neg. Biopsy confirmed Adenocarcinoma. NGS identified **EGFR L858R mutation**. PD-L1 (22C3): **TPS 60%, CPS 65, IC 2/+** (noted, but irrelevant for 1L Osimertinib choice). Started Osimertinib Feb 16, 2023.

**OBJECTIVE (Remote Assessment):**

- Appears well, energetic, NAD via video. ECOG PS 0.
- Recent Labs (drawn locally last week, reviewed): CBC, CMP (incl LFTs, Mg) all WNL.
- Recent Imaging (CT C/A/P, Aug 15, 2023 - reviewed electronically): Compared to May 2023. Stable partial response. Primary LUL nodule barely perceptible (<5mm). Osseous metastases show continued sclerosis consistent with treatment response, no new or progressive lesions.

**ASSESSMENT/PLAN:**

1. **Stage IV EGFR L858R Lung Adenocarcinoma:** Excellent ongoing clinical and radiographic response to first-line Osimertinib after 6 months. Therapy exceptionally well tolerated.
2. **Continue Osimertinib 80 mg PO daily.** Refill provided.
3. **Monitoring:** Continue monthly labs locally. Next CT C/A/P in ~3 months (Nov 2023). Continue Brain MRI surveillance q6 months (next due Jan 2024).
4. **Follow-up:** Schedule next telehealth visit in 3 months post-scans. Patient knows how to reach team with any issues.

\_\_\_\_ M.D., PhD.  
Evelyn Reed, MD, PhD (Electronically Signed)

**Patient:** Meyer, Susan Elizabeth **DOB:** 10/10/1971

**MRN SYN044**

**Date of Service:** August 23, 2023

**Visit Type:** Routine Telehealth Follow-up (Video)

**Provider:** Evelyn Reed, MD, PhD